Michael Barbella, Managing Editor03.08.21
Cross-border venture financing ended 2020 on a positive note.
Deals worth $811.3 million were recorded in the final three months of last year, representating a 31.3 percent increase compared with the third quarter and 18.2 percent vs. the last four-quarter average of $686.14 million, according to GlobalData statistics.
The top venture deal was forged by Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings, and T Rowe Price Associates.
The United States held a 64.9 percent share of the global medical devices industry cross border venture financing deal value that totalled $1.25 billion in Q4 2020.
The 24 cross border deals recorded by the United States during Q4 2020, marked a 9.09 percent increase compared with the previous quarter and a a 26.32 percent rise compared with the last four-quarter average.
The top five medical devices industry cross border venture financing deals accounted for 67.8 percent of the overall value during Q4 2020.
The combined value of the top five cross border venture financing deals stood at $550 million, against the overall value of $811.3 million recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
Deals worth $811.3 million were recorded in the final three months of last year, representating a 31.3 percent increase compared with the third quarter and 18.2 percent vs. the last four-quarter average of $686.14 million, according to GlobalData statistics.
The top venture deal was forged by Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings, and T Rowe Price Associates.
The United States held a 64.9 percent share of the global medical devices industry cross border venture financing deal value that totalled $1.25 billion in Q4 2020.
The 24 cross border deals recorded by the United States during Q4 2020, marked a 9.09 percent increase compared with the previous quarter and a a 26.32 percent rise compared with the last four-quarter average.
The top five medical devices industry cross border venture financing deals accounted for 67.8 percent of the overall value during Q4 2020.
The combined value of the top five cross border venture financing deals stood at $550 million, against the overall value of $811.3 million recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
- Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200 million venture financing of Tempus Labs
- The $150 million venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment
- 5AM Venture Management, Arboretum Ventures, CrimsoNox Capital, EDBI, Forth Management, Jazz Venture Partners, Novartis, Pilot House Ventures Group, Quad Investment Management, Sarissa Capital Management, Shanda Group, SoftBank Vision Fund II and Temasek Holdings (Private)’s $80 million venture financing of Pear Therapeutics
- The $65 million venture financing of AliveCor by Bold Capital Partners, Khosla Ventures, Omron Healthcare, Qualcomm Ventures and WP Global Partner
- Asset Management Ventures, Franklin Templeton Investments, Jonathan Fielding, King River Capital, Lightspeed Ventures, Ltd., Olive Tree Capital, SteelSky Ventures and Weili Dai’s venture financing of LARK HEALTH for $55 million.
